{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:52:34Z","timestamp":1792785154410,"version":"4.5.0"},"reference-count":50,"publisher":"Georg Thieme Verlag KG","funder":[{"name":"German Research Foundation Deutsche Forschungsgemeinschaft","award":["CRC1366 C07, project no. 394046768"],"award-info":[{"award-number":["CRC1366 C07, project no. 394046768"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Circulating amyloid \u03b2 1\u201340 (A\u03b240), a pro-inflammatory and pro-atherogenic peptide, is an emerging biomarker in atherosclerotic cardiovascular disease (ASCVD), but evidence on its modulation by cardiovascular therapies is limited and conflicting. We explored associations between statin therapy and A\u03b240 plasma levels.<\/jats:p>\n                  <jats:p>In this prospective study, patients with dyslipidemia (n\u2009=\u2009146) were consecutively recruited. \u0391\u03b240 was measured in plasma by enzyme-linked immunosorbent assay at baseline, after a mean follow-up of 5.2 (visit 2 [V2]) and 15 months (visit 3 [V3]). Patients in whom statin treatment was initiated or intensified (n\u2009=\u200968, intensification group) were compared with patients who were untreated or on stable statin intensity (n\u2009=\u200978, control group).<\/jats:p>\n                  <jats:p>After multivariable adjustment for biologically plausible confounders, increased A\u03b240 at baseline associated with ASCVD, heart failure, decreased estimated glomerular filtration rate (eGFR), and diabetes mellitus (DM). A\u03b240 increased from baseline to V2 in the intensification group (p\u2009=\u20090.05 and adjusted p for interaction\u2009=\u20090.031 vs. the control group) and then stabilized. In the control group, A\u03b240 increased at V3 compared with V2 (p\u2009=\u20090.043). Excluding ezetimibe-treated patients did not alter these findings. In patients with low-density lipoprotein cholesterol (LDL-C) reduction \u2265\u200950% at V3, A\u03b240 levels remained unchanged, whereas they increased in the rest of the population (adjusted p for group interaction\u2009=\u20090.030).<\/jats:p>\n                  <jats:p>In high-risk patients, statin initiation or intensification is associated with a short-term increase, followed by a long-term return to initial A\u03b240 circulating levels, whereas patients achieving LDL-C reduction show long-term stabilization of A\u03b240 levels. Further research is warranted to clarify the mechanistic insights of these observations.<\/jats:p>","DOI":"10.1055\/a-2958-4419","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:59:21Z","timestamp":1789426761000},"source":"Crossref","is-referenced-by-count":0,"title":["Statin Intensification and LDL Cholesterol Reduction are Associated with Longitudinal Changes in Circulating Amyloid-\u03b2 1\u201340 in a Prospective Dyslipidemia Cohort"],"prefix":"10.1055","author":[{"given":"Konstantinos","family":"Stellos","sequence":"first","affiliation":[{"name":"University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, BW, Germany","place":["Mannheim"],"department":["Department of Cardiology, Haemostaseology, and Medical Intensive Care"]},{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg\/Mannheim, Germany","place":["Mannheim"]},{"name":"Heidelberg University, Germany","place":["Mannheim"],"department":["European Center for Angioscience (ECAS)"]},{"name":"Heidelberg University, Germany","place":["Mannheim"],"department":["Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbr\u00fcck Center for Molecular Medicine in the Helmholtz Association (MDC)"]},{"name":"University Hospital Heidelberg - Medical Center Mannheim, Heidelberg University, Germany","place":["Mannheim"],"department":["Department of Medicine VI (Vascular Medicine and Diabetology)"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimon","family":"Stamatelopoulos","sequence":"first","affiliation":[{"name":"National and Kapodistrian University of Athens School of Medicine Therapeutic Clinic, Attica, Greece","place":["Athens"],"department":["Department of Clinical Therapeutics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evmorfia","family":"Aivalioti","sequence":"additional","affiliation":[{"name":"School of Medicine, National and Kapodistrian University of Athens, Athens, Greece","place":["Athens"],"department":["Department of Clinical Therapeutics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Georgiopoulos","sequence":"additional","affiliation":[{"name":"School of Medicine, National and Kapodistrian University of Athens, Athens, Greece","place":["Athens"],"department":["Department of Clinical Therapeutics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Delialis","sequence":"additional","affiliation":[{"name":"School of Medicine, National and Kapodistrian University of Athens, Athens, Greece","place":["Athens"],"department":["Department of Clinical Therapeutics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Konstantaki","sequence":"additional","affiliation":[{"name":"School of Medicine, National and Kapodistrian University of Athens, Athens, Greece","place":["Athens"],"department":["Department of Clinical Therapeutics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Patras","sequence":"additional","affiliation":[{"name":"School of Medicine, National and Kapodistrian University of Athens, Athens, Greece","place":["Athens"],"department":["Department of Clinical Therapeutics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysoula","family":"Moustou","sequence":"additional","affiliation":[{"name":"School of Medicine, National and Kapodistrian University of Athens, Athens, Greece","place":["Athens"],"department":["Department of Clinical Therapeutics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Mpatziou","sequence":"additional","affiliation":[{"name":"School of Medicine, National and Kapodistrian University of Athens, Athens, Greece","place":["Athens"],"department":["Department of Clinical Therapeutics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Mavraganis","sequence":"additional","affiliation":[{"name":"School of Medicine, National and Kapodistrian University of Athens, Athens, Greece","place":["Athens"],"department":["Department of Clinical Therapeutics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Sopova","sequence":"additional","affiliation":[{"name":"University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, BW, Germany","place":["Mannheim"],"department":["Department of Cardiology, Haemostaseology, and Medical Intensive Care"]},{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg\/Mannheim, Germany","place":["Mannheim"]},{"name":"Heidelberg University, Germany","place":["Mannheim"],"department":["European Center for Angioscience (ECAS)"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sachse","sequence":"additional","affiliation":[{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg\/Mannheim, Germany","place":["Mannheim"]},{"name":"Heidelberg University, Germany","place":["Mannheim"],"department":["European Center for Angioscience (ECAS)"]},{"name":"Heidelberg University, Germany","place":["Mannheim"],"department":["Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbr\u00fcck Center for Molecular Medicine in the Helmholtz Association (MDC)"]},{"name":"University Hospital Heidelberg - Medical Center Mannheim, Heidelberg University, Germany","place":["Mannheim"],"department":["Department of Medicine VI (Vascular Medicine and Diabetology)"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2019.12.033","article-title":"The Alzheimer's disease amyloid-beta hypothesis in cardiovascular aging and disease: JACC Focus Seminar","volume":"75","author":"D A Stakos","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/eurheartj\/ehae655","article-title":"Amyloid-beta metabolism in age-related neurocardiovascular diseases","volume":"46","author":"E Aivalioti","year":"2025","journal-title":"Eur Heart J"},{"issue":"07","key":"ref3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00259-017-3651-2","article-title":"Feasibility of in vivo 18F-florbetaben PET\/MR imaging of human carotid amyloid-\u03b2","volume":"44","author":"J Bucerius","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/01.RES.0000020017.84398.61","article-title":"Platelet phagocytosis and processing of beta-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis","volume":"90","author":"G R De Meyer","year":"2002","journal-title":"Circ Res"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1161\/CIRCULATIONAHA.109.879510","article-title":"Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy","volume":"121","author":"D Gianni","year":"2010","journal-title":"Circulation"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1055\/s-0040-1721144","article-title":"Circulating amyloid beta 1-40 is associated with increased rate of progression of atherosclerosis in menopause: a prospective cohort study","volume":"121","author":"I Lambrinoudaki","year":"2021","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"14944","DOI":"10.1038\/s41598-024-64906-8","article-title":"Amyloid beta is associated with carotid wall echolucency and atherosclerotic plaque composition","volume":"14","author":"D Delialis","year":"2024","journal-title":"Sci Rep"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"e70171","DOI":"10.1111\/eci.70171","article-title":"Amyloid-beta (1-40) peptide is associated with systemic metabolic health","volume":"56","author":"K Sopova","year":"2026","journal-title":"Eur J Clin Invest"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"e70006","DOI":"10.1111\/eci.70006","article-title":"Circulating amyloid beta 1-40 peptide as an associate of renal function decline","volume":"55","author":"G Mavraganis","year":"2025","journal-title":"Eur J Clin Invest"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"e035620","DOI":"10.1161\/JAHA.124.035620","article-title":"Amyloid \u03b21-40 predicts long-term mortality rate in patients with acute myocardial infarction","volume":"14","author":"A Aleksova","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7326\/M17-1540","article-title":"Amyloid-\u03b2 (1-40) and mortality in patients with non-ST-segment elevation acute coronary syndrome: a cohort study","volume":"168","author":"K Stamatelopoulos","year":"2018","journal-title":"Ann Intern Med"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jacc.2014.12.035","article-title":"Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease","volume":"65","author":"K Stamatelopoulos","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"105078","DOI":"10.1016\/j.neuint.2021.105078","article-title":"Lovastatin attenuates sevoflurane-induced cognitive disorder in aged rats via reducing A\u03b2 accumulation","volume":"148","author":"Y Xu","year":"2021","journal-title":"Neurochem Int"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3233\/JAD-2011-101857","article-title":"Induction of the C-terminal proteolytic cleavage of A\u03b2PP by statins","volume":"25","author":"O Descamps","year":"2011","journal-title":"J Alzheimers Dis"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s12640-020-00222-z","article-title":"Simvastatin prevents long-term cognitive deficits in sepsis survivor rats by reducing neuroinflammation and neurodegeneration","volume":"38","author":"C HR Catal\u00e3o","year":"2020","journal-title":"Neurotox Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"4864017","DOI":"10.1155\/2020\/4864017","article-title":"Rosuvastatin improves cognitive function of chronic hypertensive rats by attenuating white matter lesions and beta-amyloid deposits","volume":"2020","author":"L Zheng","year":"2020","journal-title":"BioMed Res Int"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/cns.14117","article-title":"Does statin use affect amyloid beta deposition and brain metabolism?","volume":"29","author":"F Nabizadeh","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biopha.2017.05.060","article-title":"Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b","volume":"92","author":"W Huang","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1212\/WNL.0000000000004392","article-title":"Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults","volume":"89","author":"G Li","year":"2017","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s13063-016-1370-9","article-title":"Towards onset prevention of cognition decline in adults with Down syndrome (the TOP-COG study): a pilot randomised controlled trial","volume":"17","author":"S A Cooper","year":"2016","journal-title":"Trials"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/WAD.0b013e3181d61fea","article-title":"Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers","volume":"24","author":"A Serrano-Pozo","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archneur.61.3.333","article-title":"Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins","volume":"61","author":"K H\u00f6glund","year":"2004","journal-title":"Arch Neurol"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3233\/JAD-180098","article-title":"Role of blood-brain barrier in Alzheimer's disease","volume":"63","author":"Z Cai","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma \u03b2-amyloid in Alzheimer's disease and vascular disease","volume":"6","author":"S Janelidze","year":"2016","journal-title":"Sci Rep"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bcp.12861","article-title":"The effect of LCZ696 (sacubitril\/valsartan) on amyloid-\u03b2 concentrations in cerebrospinal fluid in healthy subjects","volume":"81","author":"T H Langenickel","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"F Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"34","key":"ref27","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"F LJ Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"S 01","key":"ref28","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/07853890.1999.11904394","article-title":"An update on familial hypercholesterolaemia","volume":"31","author":"L Ose","year":"1999","journal-title":"Ann Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neulet.2007.09.058","article-title":"The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels","volume":"428","author":"L Abdullah","year":"2007","journal-title":"Neurosci Lett"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3233\/JAD-2009-0948","article-title":"Performance characteristics of plasma amyloid-beta 40 and 42 assays","volume":"16","author":"O I Okereke","year":"2009","journal-title":"J Alzheimers Dis"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000496099","article-title":"Long-term storage effects on stability of A\u03b21-40, A\u03b21-42, and total Tau proteins in human plasma samples measured with immunomagnetic reduction assays","volume":"9","author":"M J Chiu","year":"2019","journal-title":"Dement Geriatr Cogn Disord Extra"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.dadm.2019.02.002","article-title":"Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers","volume":"11","author":"M R\u00f3zga","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"issue":"25","key":"ref34","first-page":"e1046","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"S M Grundy","year":"2019","journal-title":"Circulation"},{"issue":"07","key":"ref35","first-page":"884","article-title":"Treatment and low-density lipoprotein cholesterol management in patients diagnosed with clinical atherosclerotic cardiovascular disease in Alberta","volume":"35","author":"G Chen","year":"2019","journal-title":"Can J Cardiol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"20240028","DOI":"10.59368\/agingbio.20240028","article-title":"Ezetimibe lowers risk of Alzheimer's and related dementias over sevenfold, reducing aggregation in model systems by inhibiting 14-3-3G:hexokinase interaction","volume":"2","author":"A Ganne","year":"2024","journal-title":"Aging Biol"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JAD-220240","article-title":"Effects of simvastatin on plasma amyloid-\u03b2 transport in patients with hyperlipidemia: a 12-week randomized, double-blind, placebo-controlled trial","volume":"90","author":"S Wei","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0304-3940(03)00895-4","article-title":"Pravastatin at 10 mg\/day does not decrease plasma levels of either amyloid-beta (Abeta) 40 or Abeta 42 in humans","volume":"350","author":"K Ishii","year":"2003","journal-title":"Neurosci Lett"},{"issue":"05","key":"ref39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archneur.62.5.753","article-title":"Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results","volume":"62","author":"D L Sparks","year":"2005","journal-title":"Arch Neurol"},{"issue":"07","key":"ref40","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/archneur.60.7.958","article-title":"Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels","volume":"60","author":"H Fukumoto","year":"2003","journal-title":"Arch Neurol"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbalip.2017.09.008","article-title":"Regulatory effects of simvastatin and apoJ on APP processing and amyloid-\u03b2 clearance in blood-brain barrier endothelial cells","volume":"1863","author":"M Zandl-Lang","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"02","key":"ref42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/BJ20060655","article-title":"Statins inhibit the dimerization of beta-secretase via both isoprenoid- and cholesterol-mediated mechanisms","volume":"399","author":"R B Parsons","year":"2006","journal-title":"Biochem J"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12883-015-0390-5","article-title":"Dose-specific effect of simvastatin on hypoxia-induced HIF-1\u03b1 and BACE expression in Alzheimer's disease cybrid cells","volume":"15","author":"J H Jeong","year":"2015","journal-title":"BMC Neurol"},{"issue":"29","key":"ref44","doi-asserted-by":"crossref","first-page":"22091","DOI":"10.1074\/jbc.M110.102277","article-title":"Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance","volume":"285","author":"M Shinohara","year":"2010","journal-title":"J Biol Chem"},{"issue":"06","key":"ref45","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/glia.22974","article-title":"Simvastatin and atorvastatin facilitates amyloid \u03b2-protein degradation in extracellular spaces by increasing neprilysin secretion from astrocytes through activation of MAPK\/Erk1\/2 pathways","volume":"64","author":"N Yamamoto","year":"2016","journal-title":"Glia"},{"issue":"48","key":"ref46","doi-asserted-by":"crossref","first-page":"37405","DOI":"10.1074\/jbc.M110.149468","article-title":"Statins promote the degradation of extracellular amyloid beta-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion","volume":"285","author":"I Y Tamboli","year":"2010","journal-title":"J Biol Chem"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1091\/mbc.E20-05-0345","article-title":"Cholesterol-lowering drugs reduce APP processing to A\u03b2 by inducing APP dimerization","volume":"32","author":"V F Langness","year":"2021","journal-title":"Mol Biol Cell"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3233\/JAD-150982","article-title":"Inhibition of cholesterol biosynthesis reduces \u03b3-secretase activity and amyloid-\u03b2 generation","volume":"51","author":"Y Kim","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"9493","key":"ref49","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"C Baigent","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"ref50","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.109.192278","article-title":"Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association","volume":"119","author":"M A Hlatky","year":"2009","journal-title":"Circulation"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2958-4419.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:08:52Z","timestamp":1790118532000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2958-4419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":50,"URL":"https:\/\/doi.org\/10.1055\/a-2958-4419","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,14]]},"published":{"date-parts":[[2026,9,14]]}}}